KRAS Q61L

CI-VAR-00003571Explore in graph →NP_004976.2:p.Gln61LeuNM_004985.4:c.182A>TClinVar 45116 CIViC 908 rs121913240

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm4
KRAS Q61L	Cetuximab	Predictive	B	Supports Resistance	3	submitted	EID2228 In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic
KRAS Q61L	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3866 In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45116	Pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma; Multiple myeloma; Neoplasm; Germinoma; Medullary thyroid carcinoma	somatic	5	Nov 02, 2011	clinvar